Corbus Pharmaceuticals Holding Net Assets

Latest as of June 2026: $102.24 Million USD

Corbus Pharmaceuticals Holding net assets. Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has net assets worth $102.24 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($126.99 Million) and total liabilities ($24.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CRBP net assets growth trend to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$102.24 Million
% of Total Assets	80.51%
Annual Growth Rate	N/A
5-Year Change	113.44%
10-Year Change	1553.76%
Growth Volatility	252.53

Net Assets of Corbus Pharmaceuticals Holding (2012–2025)

Net assets of Corbus Pharmaceuticals Holding from 2012 to 2025. This chart illustrates how Corbus Pharmaceuticals Holding's net assets have evolved over time, based on quarterly financial data. See how leveraged is Corbus Pharmaceuticals Holding's balance sheet to measure how much of total assets are equity-financed.

Annual Net Assets for Corbus Pharmaceuticals Holding (2012–2025)

The table below shows the annual net assets of Corbus Pharmaceuticals Holding from 2012 to 2025. For live market cap and overall valuation, see CRBP market cap.

Year	Net Assets	Change
2025-12-31	$147.50 Million	+3.56%
2024-12-31	$142.43 Million	+2162.68%
2023-12-31	$-6.91 Million	-120.93%
2022-12-31	$32.99 Million	-52.26%
2021-12-31	$69.11 Million	+52.64%
2020-12-31	$45.27 Million	+635.27%
2019-12-31	$6.16 Million	-77.63%
2018-12-31	$27.52 Million	-52.37%
2017-12-31	$57.78 Million	+547.85%
2016-12-31	$8.92 Million	-0.73%
2015-12-31	$8.99 Million	+53.26%
2014-12-31	$5.86 Million	+428.78%
2013-12-31	$-1.78 Million	-898779.93%
2012-12-31	$-198.38	--

Equity Component Analysis

This analysis shows how different components contribute to Corbus Pharmaceuticals Holding's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 55542871576.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Corbus Pharmaceuticals Holding Net Assets Breakdown (December 2025)

Corbus Pharmaceuticals Holding net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Common Stock	$2.00K	0.00%
Other Comprehensive Income	$-53.00K	-0.04%
Other Components	$702.98 Million	476.59%
Total Equity	$147.50 Million	100.00%

Corbus Pharmaceuticals Holding Competitors by Market Cap

The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their market capitalization.

Company	Market Cap
High Co. SA PA:HCO	$69.06 Million
Ganesh Benzoplast Limited NSE:GANESHBE	$69.06 Million
Bibica Corp VN:BBC	$69.11 Million
International Media Acquisition Corp NASDAQ:IMAQ	$69.12 Million
Sheh Fung Screws Co Ltd TWO:2065	$69.04 Million
Hwa Sung Ind KO:002460	$69.03 Million
Powertech Industrial Co Ltd TW:3296	$69.02 Million
Avgol Industries 1953 Ltd TA:AVGL	$69.00 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Corbus Pharmaceuticals Holding's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 142,428,000 to 147,503,000, a change of 5,075,000 (3.6%).
Net loss of 78,537,000 reduced equity.
New share issuances of 77,426,000 increased equity.
Other comprehensive income decreased equity by 88,000.
Other factors increased equity by 6,274,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-78.54 Million	-53.24%
Share Issuances	$77.43 Million	+52.49%
Other Comprehensive Income	$-88.00K	-0.06%
Other Changes	$6.27 Million	+4.25%
Total Change	$-	3.56%

Book Value vs Market Value Analysis

This analysis compares Corbus Pharmaceuticals Holding's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.32x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	$-0.85	$3.57	x
2013-12-31	$-2.07	$3.57	x
2014-12-31	$8.72	$3.57	x
2015-12-31	$8.60	$3.57	x
2016-12-31	$6.50	$3.57	x
2017-12-31	$34.55	$3.57	x
2018-12-31	$14.49	$3.57	x
2019-12-31	$2.89	$3.57	x
2020-12-31	$17.38	$3.57	x
2021-12-31	$16.86	$3.57	x
2022-12-31	$7.91	$3.57	x
2023-12-31	$-1.60	$3.57	x
2024-12-31	$13.05	$3.57	x
2025-12-31	$11.08	$3.57	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Corbus Pharmaceuticals Holding utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -53.24%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.14x
Recent ROE (-53.24%) is above the historical average (-167.66%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	0.00%	0.00%	0.00x	0.00x	$-867.12
2013	0.00%	0.00%	0.00x	0.00x	$-424.03K
2014	-43.33%	0.00%	0.00x	1.13x	$-3.13 Million
2015	-98.51%	-1365.05%	0.05x	1.43x	$-9.75 Million
2016	-224.22%	-1046.27%	0.11x	2.01x	$-20.89 Million
2017	-56.11%	-1328.65%	0.04x	1.16x	$-38.20 Million
2018	-202.27%	-1154.48%	0.10x	1.71x	$-58.42 Million
2019	-1160.42%	-197.69%	0.74x	7.98x	$-72.07 Million
2020	-245.76%	-2826.08%	0.04x	2.26x	$-115.80 Million
2021	-65.92%	-5166.42%	0.01x	1.56x	$-52.46 Million
2022	-169.24%	0.00%	0.00x	2.01x	$-59.13 Million
2023	0.00%	0.00%	0.00x	0.00x	$-43.91 Million
2024	-28.23%	0.00%	0.00x	1.09x	$-54.45 Million
2025	-53.24%	0.00%	0.00x	1.14x	$-93.29 Million

Industry Comparison

This section compares Corbus Pharmaceuticals Holding's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $211,904,180
Average return on equity (ROE) among peers: 1119.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Corbus Pharmaceuticals Holding (CRBP)	$102.24 Million	0.00%	0.24x	$69.05 Million
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-54.64 Million	0.00%	0.00x	$27.43 Million
Abcellera Biologics Inc (ABCL)	$1.15 Billion	-12.70%	0.29x	$3.53 Billion
Abeona Therapeutics Inc (ABEO)	$178.43 Million	-42.75%	0.25x	$241.32 Million
Acumen Pharmaceuticals Inc (ABOS)	$181.82 Million	-56.28%	0.31x	$15.62 Million
Abpro Holdings, Inc. (ABP)	$-14.95 Million	0.00%	0.00x	$2.00 Million
Absci Corp (ABSI)	$-41.16 Million	0.00%	0.00x	$1.41 Billion
Arbutus Biopharma Corp (ABUS)	$155.53K	11625.26%	37.80x	$804.31 Million
ABVC Biopharma Inc (ABVC)	$35.27K	-72.00%	1.50x	$26.65 Million
Abivax SA American Depositary Shares (ABVX)	$17.90 Million	-209.78%	2.98x	$7.77 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$699.13 Million	-33.65%	0.12x	$3.70 Billion

About Corbus Pharmaceuticals Holding

NASDAQ:CRBP USA Biotechnology

Market Cap

$69.05 Million

Market Cap Rank

#20469 Global

#4659 in USA

Share Price

$3.57

Change (1 day)

-7.75%

52-Week Range

$3.57 - $12.15

All Time High

$310.50